Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.

By Puyaan Singh Aug 6 (Reuters) - Eye drugmaker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial ...

Tarsus Pharmaceuticals (TARS) agreed to acquire privately held Alkeus Pharmaceuticals, gaining gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease, a rare ...

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified ...

Tarsus is gearing up for a potential FDA green light of its experimental drug to treat a common but little-known eyelid inflammation disease and is wasting no time to boost awareness around the ...

How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...

Tarsus Pharmaceuticals, Inc. (TARS) now has an approved product called XDEMVY, which is rapidly capturing the Demodex blepharitis market. The strong commercial launch is increasingly supporting ...

Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million ...

Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged ...